Hereditary breast and ovarian cancer syndrome (HBOC) is a hereditary tumor that can be definitively diagnosed by detection of germline mutation of the BRCA1 or BRCA2 gene. The HBOC Public Awareness and Management Sub-committee of the Tumor Committee, Japan Society of Obstetrics and Gynecology carried out a fact-finding survey on the status of treatment of HBOC in Japan. The directors of medical specialty teaching facilities were notified of the questionnaire by post, with the request for one respondent per facility. The response period was from 8 July 2014 to 31 March 2015. Of the 678 facilities that were asked to compete the questionnaire, 341 (50.3%) responded. The responses are shown in the respective tables. For questions with free responses, similar answers have been grouped together, and the written answers have been freely translated. Based on these results, the Japan Society of Obstetrics and Gynecology considers that the 14 conditions, including consultations by specialist staff, must be met before risk-reducing salpingo-oophorectomy is carried out.
Objectives and Outline of the Questionnaire
Hereditary breast and ovarian cancer syndrome (HBOC) is a hereditary tumor that can be definitively diagnosed by detection of germline mutation of the BRCA1 or BRCA2 gene. In other countries, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology suggest risk-reducing surgery (risk-reducing mastectomy or risk-reducing salpingo-oophorectomy [RRSO] ) as an option for cancer prevention in cases that have been definitively diagnosed with HBOC. 1 With ovarian cancer in particular, preclinical salpingo-oophorectomy is considered to be the most effective preventive method, as a method of examination that is effective for early detection has yet to be established. This procedure is therefore recommended for women of appropriate age, such as those who have no wish to conceive. In Japan, the Development of Communication Program Regarding Genetic Counseling and Testing for Breast and Ovarian Cancer Patients (Research Grant of Ministry of Education, Culture, Sports, Science and Technology, 1 April 2012-31 March 2015) group carried out a fact-finding survey on HBOC among specialists in gynecologic oncology by administering the report as "a survey of the practice patterns of gynecologic oncologists dealing with hereditary cancer patients in Japan." 2 The results of this study showed that a cooperative response to HBOC by obstetrician-gynecologists, clinical geneticists, and certified genetic counselors was an urgent issue. In addition, it was found that: 9.5% of facilities (n = 306) are able to carry out RRSO; some of these facilities carry out more than 50 procedures a year; and 25% of these facilities carry out this procedure as regular medical care. While the survey carried out by this research group was aimed at specialists in gynecologic oncology, it was anonymous, and the results showed that, with insufficient response to the needs and with no treatment systems in place in Japan, there are concerns that inappropriate medical care may be given to HBOC patients. Given this situation, the HBOC Public Awareness and Management Sub-committee of the Tumor Committee, Japan Society of Obstetrics and Gynecology (JSOG) carried out a fact-finding survey on HBOC medical treatment in Japan with the aim of constructing a system for appropriate examinations. Specifically, a questionnaire on HBOC medical care was given to the core facilities of JSOG, the results of which are presented here. In addition, views regarding RRSO for persons with mutations of the BRCA1 or BRCA2 gene based on an analysis of the results are shown.
Methods
The present questionnaire was approved by the Clinical Research Review Board of JSOG. The directors of medical specialty teaching facilities were notified of the questionnaire by post, with the request for one respondent per facility. The questionnaire was administered online from the homepage of JSOG. The response period was from 8 July 2014 to 31 March 2015.
The questionnaire items were as follows. Views regarding RRSO for women with mutations of BRCA1 and BRCA2
Women who have mutations of the BRCA1 or BRCA2 genes (BRCA1/2), which are both genes that cause HBOC, have a lifelong, high risk of breast and ovarian cancers. The risk of ovarian cancer is reported to be 39-46% in women with mutation of the BRCA1 gene and 12-27% in women with mutation of the BRCA2 gene. JSOG believes that it is essential that the risk of ovarian and/or breast cancer for individuals with the BRCA1/2 gene mutation is understood, and that appropriate measures are taken when obstetrics and gynecology departments make diagnoses. Risk assessment, genetic counseling, genetic testing, interpretation of test results, and HBOC surveillance (monitoring) are all necessary steps in the treatment of hereditary tumors. General obstetrician-gynecologists may be assumed to be the main persons involved in risk assessment and HBOC management, but when a patient is being treated for HBOC, this should be done in collaboration with an expert in clinical genetics who is fully conversant with hereditary tumors.
Studies have shown that 10-15% of patients with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer have the BRCA1/2 gene mutation. On this basis, risk assessment should be carried out with reference to the genetic evaluation standards of the NCCN Guidelines, and if the criteria are met, consideration should be given to the provision of genetic counseling and to presentation of the significance and possibilities raised by BRCA1/2 testing.
The options available to women with the BRCA1/2 gene mutation for prevention of ovarian cancer are RRSO and chemoprevention with oral contraceptives T. Satoh et al.
as primary prevention (to prevent cancer), and strict surveillance, and so forth, as secondary prevention (for early detection and early treatment of cancer). RRSO is the most reliable prevention of ovarian cancer for women with the BRCA1/2 gene mutation at this point. In addition, RRSO not only reduces the risk of ovarian cancer onset, it has also been reported to be effective in reducing the initial diagnosis of breast cancer and prolonging overall survival. For this reason, RRSO is recommended in the guidelines of other countries.
RRSO involves the ethical issue of removing internal organs that are likely to be (phenotypically) healthy. In addition, cooperation with a department that can provide pathological diagnosis of occult cancer or the presence of precancerous lesions in the epithelium of the fallopian tubes is needed. JSOG therefore considers that the following conditions must be met before RRSO is carried out.
System prior to carrying out RRSO 1 HBOC genetic counseling must be carried out at a facility that has specialist staff. In the cases of a positive test result for BRCA1/2 gene mutation, genetic counseling is carried out again, and the client's autonomy and wishes concerning RRSO must be respected. 2 Sufficient counseling and information provision must be given with regard to the efficacy and adverse effects of RRSO, including whether the client wishes to have a baby, the cancer risk, and the extent to which RRSO can prevent breast cancer and ovarian cancer, as well as possible future health effects, such as ovarian deficiency symptoms, osteoporosis, and cardiovascular disease, and their countermeasures.
Candidates for RRSO
3 As a general rule, candidates for RRSO are women with no ovarian cancer who are shown to have a pathological BRCA1/2 gene mutation (or a mutation that can be determined pathologically and clinically). 4 The timing of RRSO should depend on the individual, but carrying out the procedure after the client has finished child bearing and reached an age of 35-40 years, or at the earliest age when someone in the client's family lineage has been diagnosed with ovarian cancer, is generally considered desirable.
Facilities carrying out RRSO
5 Facilities carrying out RRSO must be reviewed by an ethics committee established within the hospital.
6 Facilities carrying out RRSO must have a system in place for HBOC genetic counseling. 7 To carry out RRSO, a facility must have a full-time specialist of the Japan Society of Gynecologic Oncology or be able to create a system of collaboration with a specialist. 8 There must be a system of cooperation in place with pathologists who have a full understanding of the handling of biopsy samples. 9 Because RRSO results in surgical menopause, there are concerns over menopausal symptoms, such as ovarian deficiency symptoms, and negative effects on the lipid profile and bone metabolism. For this reason, followup by an obstetrics and gynecology specialist who is well versed in women's health care is needed. Hormone-replacement therapy is useful for health promotion following RRSO for women with no history of breast cancer, and it is reported to have little effect on the risk of breast cancer over the short term.
Management of RRSO
10 Although combined hysterectomy is not considered necessary in association with RRSO, it has advantages when hormone therapy for breast cancer or hormone replacement therapy for ovarian deficiency symptoms is carried out. For this reason, the advantages and disadvantages of combined hysterectomy associated with RRSO should be fully explained prior to surgery. 11 Discovery of occult cancer when RRSO is carried out has been reported. The development of tumors in the neighborhood of the fimbria of the fallopian tubes has attracted attention in ovarian cancer, so that completely sectioned specimens of biopsy samples must be prepared. It is therefore essential to create a system of cooperation with the diagnostic pathology department. 12 It must be explained that even after RRSO, there is still a 2-5% probability of peritoneal cancer. 13 RRSO is recommended as primary prevention for ovarian cancer in the various guidelines. At the same time, there is no reliable method of ovarian cancer screening for women with a BRCA1/2 gene mutation who have opted not to have RRSO. Transvaginal ultrasound and CA125 measurement at least once every 6 months is considered to be a realistic secondary prevention method in actual clinical settings. However, this must be carried out with the understanding that, even though the previous examination gave a negative result, there is still a risk of so-called interval cancer, which means that Questionnaire report regarding HBOC in Japan subjective symptoms may appear and cancer may be discovered before the time of the next examination. 14 Regardless of whether RRSO is carried out, the risk of breast cancer, pancreatic cancer, or prostate cancer is increased in individuals with BRCA1/2 gene mutation. Surveillance in cooperation with the relevant departments is therefore needed even after RRSO is carried out.
